MX2023002945A - Moléculas multiespecíficas con direccionamiento inmunitario y usos de estas. - Google Patents

Moléculas multiespecíficas con direccionamiento inmunitario y usos de estas.

Info

Publication number
MX2023002945A
MX2023002945A MX2023002945A MX2023002945A MX2023002945A MX 2023002945 A MX2023002945 A MX 2023002945A MX 2023002945 A MX2023002945 A MX 2023002945A MX 2023002945 A MX2023002945 A MX 2023002945A MX 2023002945 A MX2023002945 A MX 2023002945A
Authority
MX
Mexico
Prior art keywords
antibodies
specific immune
targeting molecules
immune targeting
methods
Prior art date
Application number
MX2023002945A
Other languages
English (en)
Inventor
Sanjaya Singh
Rajkumar Ganesan
Iqbal S Grewal
Michael Riis Hansen
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2023002945A publication Critical patent/MX2023002945A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

En la presente descripción se proporcionan anticuerpos triespecíficos o fragmentos de unión al antígeno de estos que se unen a Vß17, CD28 y otra objetivo (p. ej., un antígeno de cáncer, tal como BCMA o PSMA) se describen. También se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos, y métodos para usar los anticuerpos para tratar o prevenir enfermedades.
MX2023002945A 2020-09-11 2021-09-10 Moléculas multiespecíficas con direccionamiento inmunitario y usos de estas. MX2023002945A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063077415P 2020-09-11 2020-09-11
US202063077458P 2020-09-11 2020-09-11
US202063077407P 2020-09-11 2020-09-11
US202163165050P 2021-03-23 2021-03-23
PCT/US2021/049769 WO2022056199A1 (en) 2020-09-11 2021-09-10 Multi-specific immune targeting molecules and uses thereof

Publications (1)

Publication Number Publication Date
MX2023002945A true MX2023002945A (es) 2023-06-12

Family

ID=80629898

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002945A MX2023002945A (es) 2020-09-11 2021-09-10 Moléculas multiespecíficas con direccionamiento inmunitario y usos de estas.

Country Status (11)

Country Link
US (1) US20220089737A1 (es)
EP (1) EP4211172A1 (es)
JP (1) JP2023540799A (es)
KR (1) KR20230084507A (es)
AU (1) AU2021338776A1 (es)
CA (1) CA3194752A1 (es)
IL (1) IL301242A (es)
MX (1) MX2023002945A (es)
TW (1) TW202227494A (es)
UY (1) UY39416A (es)
WO (1) WO2022056199A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
KR20230084508A (ko) 2020-09-11 2023-06-13 얀센 바이오테크 인코포레이티드 베타 사슬 매개 면역을 조절하기 위한 방법 및 조성물
WO2022056197A1 (en) * 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
US20220267438A1 (en) * 2021-02-16 2022-08-25 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN117187180B (zh) * 2023-11-03 2024-01-26 四川大学 一种Th17细胞及其培养方法和应用及其诱导液

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013217A (es) * 2005-04-25 2008-03-11 Pfizer Anticuerpos contra miostatina.
AU2009246946B2 (en) * 2008-05-01 2013-09-26 Amgen Inc. Anti-hepcidin antibodies and methods of use
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014159531A1 (en) * 2013-03-14 2014-10-02 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting epcam for detection of prostate cancer lymph node metastases
TWI718992B (zh) * 2014-07-21 2021-02-21 瑞士商諾華公司 使用cll-1嵌合抗原受體治療癌症
AR104250A1 (es) * 2015-04-16 2017-07-05 Eisai R&D Man Co Ltd Anticuerpo anti-notch4 humano
JO3711B1 (ar) * 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US10800843B2 (en) * 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
CA2997444A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
WO2018187799A1 (en) * 2017-04-07 2018-10-11 The Rockefeller University Compositions and methods related to human neutralizing antibodies to zika and dengue 1 virus
EP3706803A4 (en) * 2017-11-08 2021-08-04 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. CONJUGATES OF BIOMOLECULES AND THEIR USES
TW202015719A (zh) * 2018-06-19 2020-05-01 美商尼恩醫療公司 新抗原及其用途
EP3818083A2 (en) * 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CA3125345A1 (en) * 2019-01-04 2020-07-09 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020183245A2 (en) * 2019-03-11 2020-09-17 Janssen Pharmaceutica Nv ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES
AU2020298324A1 (en) * 2019-06-21 2022-01-27 Single Cell Technology, Inc. Anti-TIGIT antibodies
AU2020359070A1 (en) * 2019-10-03 2022-04-21 Janssen Biotech, Inc. Methods for producing biotherapeutics with increased stability by sequence optimization
TW202144415A (zh) * 2020-02-27 2021-12-01 美商健生生物科技公司 用於調節免疫反應的材料及方法

Also Published As

Publication number Publication date
CA3194752A1 (en) 2022-03-17
TW202227494A (zh) 2022-07-16
KR20230084507A (ko) 2023-06-13
AU2021338776A1 (en) 2023-05-25
IL301242A (en) 2023-05-01
EP4211172A1 (en) 2023-07-19
US20220089737A1 (en) 2022-03-24
WO2022056199A1 (en) 2022-03-17
JP2023540799A (ja) 2023-09-26
UY39416A (es) 2022-03-31

Similar Documents

Publication Publication Date Title
MX2023002945A (es) Moléculas multiespecíficas con direccionamiento inmunitario y usos de estas.
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
CR20210326A (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
PH12018500520A1 (en) Cd3 binding polypeptides
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
MX2019009967A (es) Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas.
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
MX2022004042A (es) Proteinas de union multiespecificas para tratamiento contra el cancer.
EA201790799A1 (ru) Композиции и способы для применения для усиления иммунного ответа и терапии злокачественных опухолей
PH12020551907A1 (en) Antagonizing cd73 antibody
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
WO2019217145A8 (en) Anti-dll3 antibodies and uses thereof
JOP20210085A1 (ar) أجسام مضادة لـ TNF- alpha وشظايا وظيفية منها
NZ761636A (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2023002948A (es) Métodos y composiciones para modular la inmunidad mediada por cadena beta.
AU2018345715A8 (en) DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
CR20210548A (es) Materiales y métodos para modular la inmunidad mediada por células t
WO2021058711A3 (en) Antigen binding proteins